Rectal Indomethacin in the Prevention of Post-Endoscopic Retrograde Cholangiopancreatography (ERCP) Pancreatitis in High Risk Patients
| Status: | Archived |
|---|---|
| Conditions: | Gastrointestinal |
| Therapuetic Areas: | Gastroenterology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | January 2009 |
| End Date: | December 2011 |
A Prospective, Randomized, Controlled Trial of Rectal Indomethacin in the Prevention of Post-ERCP Pancreatitis in High Risk Patients.
Pancreatitis (inflammation of the pancreas) is the most common complication of endoscopic
retrograde cholangiopancreatography (ERCP), a procedure for the diagnosis and treatment of
disorders of the pancreas and bile duct.
Preliminary data has shown that non-steroidal antiinflammatory drugs, when administered
rectally, can reduce the risk of pancreatitis after ERCP. This study is intended to
definitively determine whether rectally administered indomethacin (a non-steroidal
antiinflammatory drug)is effective at preventing pancreatitis after ERCP.
This study is a multi-center, randomized, placebo-controlled, double-blinded clinical trial
of rectal indomethacin in the prevention of post-ERCP pancreatitis in high risk patients.
We found this trial at
2
sites
1500 E Medical Center Dr
Ann Arbor, Michigan 48109
Ann Arbor, Michigan 48109
(734) 936-4000
University of Michigan Health Systems The University of Michigan is home to one of the...
Click here to add this to my saved trials
Click here to add this to my saved trials